Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.

Item
http://www.wikidata.org/entity/Q44582795
Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders.Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 studyCurrent and future management of Ph/BCR-ABL positive ALL.Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia.FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia.Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL.Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
P2860

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.

Item
http://www.wikidata.org/entity/Q44582795
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Serial minimal residual diseas ...... LL) during imatinib treatment.
@en
Serial minimal residual disease
@nl
type
label
Serial minimal residual diseas ...... LL) during imatinib treatment.
@en
Serial minimal residual disease
@nl
prefLabel
Serial minimal residual diseas ...... LL) during imatinib treatment.
@en
Serial minimal residual disease
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Serial minimal residual diseas ...... LL) during imatinib treatment.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P698